Accendra Health, Inc. (ACH) FinancialsACHFinancialAccendra Health, Inc.

Accendra Health, Inc. (ACH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes, accounting for 32.4% of total sales, equivalent to $198.82M. Other significant revenue streams include Sleep therapy and Home respiratory therapy. Understanding this composition is critical for investors evaluating how ACH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Accendra Health, Inc. maintains a gross margin of 38.22%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.49%, while the net margin is -14.52%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ACH converts its operational activities into shareholder value.

In the context of the broader market, ACH competes directly with industry leaders such as SKIN and HYPR. With a market capitalization of $93.05M, it holds a leading position in the sector. When comparing efficiency, ACH's gross margin of 38.22% stands against SKIN's 68.42% and HYPR's 50.72%. Such benchmarking helps identify whether Accendra Health, Inc. is trading at a premium or discount relative to its financial performance.

Accendra Health has shown a decline in total revenue, with Q2 2026 revenue at $613.2 million, down from $681.9 million in Q2 2025. The company also reported a widening net loss of $89.1 million in Q2 2026, reflecting deteriorating financial health.